Back to results
US 8,507,271 B2Granted
Cells useful for immuno-based botulinum toxin serotype A activity assays
AssigneeAllergan, Inc.
InventorsHong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
Life of this patent
Estimating the term…
Abstract
The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
Claims5
An established single cell derived clonal cell line from a parental SiMa cell line DSMZ ACC 164 comprising cells susceptible to intoxication by botulinum toxin type A (BoNT/A),
- wherein the cells exhibit at least a 1.5-fold increase in mRNA expression levels before differentiation in the genes ALCAM, DOK5, ERK, GFRA2, PP1/PP2A, PP2A, PPP1R3C and PPP2R2B relative to the mRNA expression levels of each of these genes in cells from a 2D6 derived from the parental SiMa cell line DSMZ ACC 164;
- and,
- wherein the cells exhibit at least a 1.5-fold decrease in mRNA expression levels before differentiation in the genes ANK2, ANK3, PHKA2, PPP2R2C and SCN2A as compared to the mRNA expression levels of each of these genes in cells from 2D6 cell line;
- and,
- wherein the clonal cell line comprises cells susceptible to BoNT/A intoxication by about 100 pM or less of a BoNT/A.
2 more elements
Dependencies are inferred from the claim text.